Wegovy (semaglutide) will no longer be available through Hims & Hers Health, as Novo Nordisk has ended its short-lived partnership.

Just two days after Novo Nordisk launched Wegovy (semaglutide 2.4 mg) in India, Eli Lilly received regulatory approval for the KwikPen® format of its rival therapy Mounjaro (tirzepatide) ...

A PIL has claimed that licences for these drugs were issued without adequate data or India-specific trials and studies, ...

VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

There is always a challenging moment in every investor’s favorite stock and portfolio, especially when said businesses are ...

Our writer reveals what he thinks is the most exciting from the four investments he made in his Stocks and Shares ISA last ...